The TLR agonist profilin protein from Toxoplasma gondii generates protection in an experimental vaccine

NADIA ARCON, MARIANO SERGIO PICCHIO, VANESA ROXANA SANCHEZ, IGNACIO MARTIN FENOY, ROSALIA ESTHER MORETTA, MATIAS DAMIAN PERRONE SIBILIA, ARIADNA SOLEDAD SOTO, MARIA DE LOS ANGELES ALDIRICO, ALEJANDRA GOLDMAN, VALENTINA MARTIN

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

Toxoplasmosis is a disease that affects 30% of the world?s population.At present, there are no pharmacological treatments thateliminate the parasite or vaccines that confer protection to the host.In this work, we studied the adjuvant and/or immunogenic value of arecombinant form of T. gondii Profilin protein (rTgPF), a TLR ligand,in a vaccine strategy using a murine model of chronic toxoplasmosis.BALB/c mice were intradermal immunized 3 times with a 2-weekinterval with: rGRA7 (recombinant T. gondii dense granule 7 protein),rTgPF, rGRA7+rTgPF or rGRA7+ACF.The anti-GRA7 humoralresponse showed a Th1 profile when rTgPF was used as adjuvant(IgG1/IgG2a ratio: 0,6±0,5), while rGRA7+ACF showed a mixedprofile (IgG1/IgG2a ratio: 1,3±0,5). Splenocytes from rGRA7+rTgPFand rGRA7+ACF mice stimulated with rGRA7, showed similar levelsof proliferative responses that were significantly higher than the controlgroup (p